Ochsner Health announced Paul J. Kenny, PhD as the 2020 recipient of the annual Alton Ochsner Award Relating Smoking and Disease, which recognizes scientific research achievements that provide major insights into the biological mechanisms relating tobacco smoking and human disease.
July 8, 2020—Ochsner Health, Louisiana's largest non-profit academic healthcare system, annouced Paul J. Kenny, PhD, as the recipient of the 35th annual Alton Ochsner Award Relating Smoking and Disease. Kenny is a Ward-Coleman professor and chair of the Nash Family Department of Neuroscience at the Icahn School of Medicine at Mount Sinai in new York.
The award is named after Alton Ochsner, MD, who, in 1939, published the first evidence indicating tobacco smoking was the makor cause of lung cancer. Kenny's research focused on nicotine addiction and provided insights for the development of new treatment methods. In particular, Kenny demonstrated the relevance of glucagon-like peptide to the regulation of nicotine craving.
"As our 2020 honoree, Dr. Kenny joins the ranks of other research giants in this field for his contributions studying nicotine addition,” said Leonardo Seoane, MD, chief academic officer of Ochsner Health.
Read the full press release here.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More